



Published in final edited form as:

*Cleft Palate Craniofac J.* 2013 January ; 50(1): 96–103. doi:10.1597/11-132.

## The *FGF* & *FGFR* Gene Family and Risk of Cleft Lip with/without Cleft Palate

**Hong Wang, Ph.D.,**

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.

**Tianxiao Zhang, M.S.,**

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

**Tao Wu, Ph.D.,**

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.

**Jacqueline B. Hetmanski, M.S.,**

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

**Ingo Ruczinski, Ph.D.,**

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

**Holger Schwender, Ph.D.,**

Faculty of Statistics, TU Dortmund University, Dortmund, Germany.

**Kung Yee Liang, Ph.D.,**

Department of Life Sciences and Institute of Genome sciences, National Yang-Ming University, Taipei, Taiwan.

**Tanda Murray, M.S.,**

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

**M. Daniele Fallin, Ph.D.,**

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

**Richard J. Redett, M.D.,**

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

**Gerald V. Raymond, M.D.,**

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

**Sheng-Chih Jin, M.S.,**

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

**Yah-Huei Wu Chou, Ph.D.,**

Chang Gung Memorial Hospital, Taipei, Taiwan.

**Philip Kuo-Ting Chen, M.D.,**

Chang Gung Memorial Hospital, Taipei, Taiwan.

**Vincent Yeow, M.D.,**

Department of Plastic Surgery, K K Womens and Childrens Hospital, Singapore.

---

Address correspondence to: Dr. Hong Wang 38 Xueyuan Road, Hai Dian District, Beijing, China. Beijing 100191 Phone: 86-10-82801619 Fax: 86-10-62029862 hwang2010@yahoo.cn.

The authors declare that they have no conflict of interest.

**Samuel S. Chong, M.D.,**  
National University of Singapore, Singapore.

**Felicia S. H. Cheah, Ph.D.,**  
National University of Singapore, Singapore.

**Sun Ha Jee, Ph.D.,**  
Institute for Health Promotion, Yonsei University, Seoul, Korea.

**Ethylin W. Jabs, M.D., Ph.D.,**  
Mount Sinai School of Medicine, New York City, New York USA.

**Alan F. Scott, Ph.D.,** and  
Johns Hopkins University School of Medicine, Baltimore, MD, USA.

**Terri H. Beaty, Ph.D.**  
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

## Abstract

**Background**—Isolated, non-syndromic cleft lip with or without cleft palate (iCL±P) is a common human congenital malformation with a complex and heterogeneous etiology. Genes coding for fibroblast growth factors and their receptors (*FGF/FGFR* genes) are excellent candidate genes.

**Methods**—We tested single nucleotide polymorphic (SNP) markers in 10 *FGF/FGFR* genes (including *FGFBP1*, *FGF2*, *FGF10*, *FGF18*, *FGFR1*, *FGFR2*, *FGF19*, *FGF4*, *FGF3*, and *FGF9*) for genotypic effects, interactions with one another, and with common maternal environmental exposures in 221 Asian and 76 Maryland case-parent trios ascertained through a child with iCL±P.

**Results**—Both *FGFR1* and *FGF19* yielded evidence of linkage and association in the transmission disequilibrium test, confirming previous evidence. Haplotypes of three SNPs in *FGFR1* were nominally significant among Asian trios. Estimated ORs for individual SNPs and haplotypes of multiple markers in *FGF19* ranged between 1.31-1.87. We also found suggestive evidence of maternal genotypic effects for markers in *FGF2* and *FGF10* among Asian trios. Tests for gene-environment (GxE) interaction between markers in *FGFR2* and maternal smoking or multivitamin supplementation yielded significant evidence of GxE interaction separately. Tests of gene-gene (GxG) interaction using Cordell's method yielded significant evidence between SNPs in *FGF9* and *FGF18*, which was confirmed in an independent sample of trios from an international consortium.

**Conclusion**—Our results suggest several genes in the *FGF/FGFR* family may influence risk to iCL±P through distinct biological mechanisms.

## Keywords

*FGF/FGFR*; oral clefts; maternal effects; gene-environment interaction; gene-gene interaction

---

Isolated, non-syndromic cleft lip with or without cleft palate (iCL±P) represents one of the most common human birth defects (Mossey and Little, 2002) and has a complex and heterogeneous etiology that remains poorly understood (Jugessur and Murray, 2005). There is a strong genetic component to the etiology of this common birth defect. A multifactorial threshold model of inheritance reflecting multiple distinct causal genes is often assumed (Grosen et al., 2010). Genome-wide linkage screens in multiplex families have shown multiple regions of the genome may harbor causal genes with a high degree of linkage heterogeneity (Marazita et al., 2004; 2009). Recently, genome wide association studies (GWAS) have identified a region on chromosome 8q24 as strongly associated with risk to

iCL±P; although it is relatively devoid of genes, raising the possibility that non-coding genetic regions are also critical (Birnbbaum et al., 2009; Grant et al., 2009; Beaty et al., 2010). Several studies have also shown suggestive evidence for interaction between candidate genes and environmental risk factors, especially maternal smoking (Zeiger et al., 2005; Shi et al., 2007a) and nutrient intake (Shaw et al., 1998) in controlling risk for iCL±P, although the evidence for gene environment (GxE) interaction remains difficult to confirm. Therefore, genes and regulatory elements outside of coding regions, plus their possible interactions with one another (GxG interaction) and with environmental factors, should be considered when searching for potential causal genes for iCL±P.

Genes in the fibroblast growth factor (*FGF*) signaling pathway are excellent candidate genes for iCL±P (Nie et al., 2006; Riley et al., 2007a; 2007b; 2007c; Menezes et al., 2008). Here we tested markers in 10 *FGF* and *FGFR* genes for their potential role in controlling risk to iCL±P using 297 case–parent trios from four populations.

## MATERIALS AND METHODS

### Sample description

As part of an international study, we collected peripheral blood, environmental exposures, and other data on iCL±P case-parent trios recruited through treatment centers in Maryland (MD), (Johns Hopkins and University of Maryland), Chang Gung Memorial Hospital in Taiwan (TW), KK Women's and Children's Hospital in Singapore (SP), and Yonsei Medical Center in South Korea (KR). History of maternal exposure to cigarette smoking, alcohol consumption, and vitamin supplementation was collected from a personal interview of mothers covering the peri-conceptual period (three months before conception through the first trimester). All probands underwent clinical genetic evaluation (including checking for other congenital anomalies or major developmental delays) and were classified as having an isolated, non-syndromic iCL±P. Research protocols were reviewed and approved by institutional review boards (IRBs) at each participating institution.

### SNP selection, DNA & genotyping

SNPs were selected in 10 *FGF/FGFR* genes (including *FGFBP1*, *FGF2*, *FGF10*, *FGF18*, *FGFR1*, *FGFR2*, *FGF19*, *FGF4*, *FGF3*, and *FGF9*) with a goal of identifying one SNP per 5kb of physical distance. Because Hapmap data were not fully available at the time our SNPs were chosen, we could not identify all possible tagging SNPs. Variants with “SNP scores” > 0.6 (an assessment of design quality of the Illumina assay based on a proprietary algorithm), high validation levels in dbSNP (including validation on multiple platforms), and high heterozygosity levels (particularly in multiple populations) were given priority. SNP markers were genotyped using Illumina's Golden-Gate chemistry at the Genetic Resources Core Facility (GRCF) at Johns Hopkins. Two duplicates and four controls from the Centre d'Etude du Polymorphisme Humain (CEPH) collection were included on each plate to evaluate genotyping consistency within and between plates.

### Statistical analysis

Genotyping rate, minor allele frequency (MAF), pairwise linkage disequilibrium (LD) and Hardy-Weinberg equilibrium (HWE) were evaluated within each population and in three Asian populations combined. LD was measured as  $r^2$  for all SNPs using Haploview (Barrett et al., 2005). SNPs were tested when the following criteria were satisfied: MAF > 1%, compatibility with HWE at  $p > 0.01$  in each group and overall genotyping rate > 80%. None of the SNPs between different *FGF/FGFR* genes on the same chromosome were in LD (data not shown), so the 10 *FGF/FGFR* genes were analyzed separately.

Statistical significance of transmission distortion from parents to the affected offspring was evaluated using the family based association test (FBAT; <http://www.biostat.harvard.edu/~fbat/fbat.htm>) for each individual SNP and for haplotypes of multiple SNPs (Laird and Lange, 2006). Numbers of transmitted and non-transmitted alleles for both single SNPs and haplotypes were generated using PLINK (v1.07; <http://pngu.mgh.harvard.edu/purcell/plink/>, Purcell et al., 2007). The 95% confidence interval (95%CI) for estimated odds ratios (ORs) of over-transmission were calculated by a binomial exact test in STATA (v 10.0).

Analysis of maternally mediated *in utero* effects was tested using TRIad Multi-Marker (TRIMM) package under an assumption of mating symmetry in the population (Shi et al., 2007b). Paired difference counts (D) of the number of target alleles carried by father and mother is a key component in constructing standardized normal (Z) statistics for the mean D across all markers, and the maximum  $Z^2$  served as a test statistic. Empiric significance of maternal genotypic effects was evaluated by permuting these max\_  $Z^2$  values over random reassignments of “father” and “mother”. To optimize power, max\_  $Z^2$  and Hotelling's  $T^2$  tests were used to generate a combined P-value (sum\_logP) from these two tests. If the global max\_  $Z^2$  test gave a  $p < 0.1$ , the apparent risk allele or haplotype was used in the log-linear framework originally proposed by Weinberg et al. (1998) to estimate relative risks. ORs and their significance associated with the mother's carrying one copy ( $S_1$ ) of the risk allele/haplotype was assessed by a likelihood ratio test (LRT) under the log-additive model (where ORs associated with carrying two copies is simply  $S_1^2$ ) as implemented in the Triad Multi-Marker relative risk Estimation program (TRIMMEST) ([www.niehs.nih.gov/research/atniehs/labs/bb/staff/weinberg](http://www.niehs.nih.gov/research/atniehs/labs/bb/staff/weinberg); Shi et al., 2009). A general model was used to estimate the OR for *FGF2*, where 4 haplotypes were present, but a more restricted model assuming HWE was used for *FGF10* where 11 haplotypes were observed (because the more general model would have required too many parameters).

Family based association tests for individual SNPs or 2-3 SNP sliding window haplotypes incorporating a GxE interaction term with maternal smoking and vitamin supplementation were performed in a combined 2 degree of freedom ( $df$ ) score test for main effects of genotype (G) and GxE interaction together, followed by a 1  $df$  score test for GxE interaction alone using PBAT (v3.6; <http://www.biostat.harvard.edu/~clange/default.htm>).

We used Cordell's (2002) LRT for possible GxG interaction assessment among markers in these 10 *FGF/FGFR* genes. Using a conditional logistic regression model, the observed 2-locus genotype of the case was compared to the 15 possible ‘pseudo-sib’ control genotypes, generating a 4  $df$  test. To address the issue of multiple comparisons, we carried out permutation tests where case vs. pseudo-sib control status was randomly shuffled 1000 times for each trio to generate new sets of data under the null hypothesis. An empirical P-value for the most significant SNP was determined by comparing the observed test statistic to these 1000 replicates.

Although markers in these 10 *FGF/FGFR* genes were typed as part of a candidate gene study conducted before the international consortium described by Beaty et al. (2010), 157 of these 297 (52.9%) case-parent trios went into that genome wide study. In a confirmatory analysis of GxG interaction, we removed these overlapping trios from the international consortium data set and used all remaining case-parent trios (n=1434) which represents an independent replication sample of iCL±P case-parent trios.

## RESULTS

A total of 297 trios were collected from four populations (MD, TW, SP and KR), and Table 1 lists gender and race of all iCL±P probands. Among the 122 SNPs genotyped in these 10

*FGF/FGFR* genes, nine SNPs were dropped due to low MAF and another 2 SNPs were dropped due to low genotyping call rate. Genotype distributions for the remaining 111 SNPs were all compatible with HWE (data not shown).

When analyzing transmission distortion of individual SNPs among these 10 *FGF/FGFR* genes, two independent markers in *FGF19* showed nominally significant evidence of linkage and association ( $P < 0.05$ ) with  $iCL \pm P$  among Asian trios, and another SNP was significant only among MD trios (Table 2). Estimated ORs for carrying the apparent high-risk allele at each of these three *FGF19* SNPs ranged from 1.37 to 1.87. Analysis of sliding window haplotypes using 2-5 SNPs together confirmed the significance of markers in *FGF19* among Asian trios, and a 3-SNP haplotype in *FGFR1* (*rs6987534*, *rs6474354* and *rs10958700*) gave  $p = 0.04$  (corrected  $p = 0.30$ ) among Asian trios.

In testing for possible maternal genotype effects, one 4-SNP haplotype in *FGF2* and another 6-SNP haplotype in *FGF10* showed significant empiric evidence of an increased risk of  $iCL \pm P$  in offspring that depended solely upon maternal genotype among Asian trios. The corresponding ORs for the child being affected were estimated as 1.72 ( $\chi^2 = 11.47$ , empiric  $p = 0.0007$ ) and 1.61 ( $\chi^2 = 7.29$ , empiric  $p = 0.0069$ ), if the mother carried one copy of the risk haplotype (Table 3).

Although the rate of maternal alcohol consumption was too low to permit separate analysis, about 5% and 25% Asian mothers reported smoking and taking vitamin supplements, respectively, during the critical peri-conceptual period (Sull et al., 2009). Significant evidence of GxE interaction was seen among Asian populations for *FGFR2* (Figure 1). For GxSmoking analysis, the most significant evidence was seen in a 2-SNP haplotype (*rs2981428* and *rs3750817*) which yielded a  $p = 0.0058$  in a 1 *df* test (Figure 1) which is not significant after strict Bonferroni correction. For GxVitamin interaction, the strongest evidence in *FGFR2* was seen both in 1 *df* test for a single SNP (*rs2912771*;  $p = 0.00027$ , corrected  $p = 0.042$ ) and in the 2 *df* test for a 3-SNP haplotype (involving *rs4752566*, *rs2912760*, and *rs3135761*;  $p = 0.00021$ , corrected  $p = 0.033$ ). These P-values for GxVitamin interaction remained significant after strict Bonferroni correction for all 156 tests conducted on the 27 markers and their haplotypes in *FGFR2*. As seen in the lower panel of Figure 1, several other SNPs and haplotypes also showed nominal significance in either the 1 *df* or the 2 *df* test for GxVitamin interaction.

A total of 16 pairs of SNPs in different *FGF* genes attained nominal significance in tests of GxG interaction (Table 4). The most significant LRT was generated by *rs2043278* in *FGF18* and *rs12870202* in *FGF9* ( $p = 0.0001$ ), which remained significant ( $p = 0.019$ ) after correcting for multiple comparisons via permutation tests. Only 1.9% of replicates (across the 338 separate tests for GxG interactions) generated under the null hypothesis exceeded this observed test statistic (Table 4 and Figure 2).

To follow-up on the intriguing evidence for GxG interaction between *FGF9* and *FGF18* seen here, an independent replication sample of 1,434 case-parent trios was examined in a confirmatory test of GxG interaction using markers in these two genes. Only *rs2043278* in *FGF18* was included in the genome wide marker panel, but 11 different SNPs in or near *FGF9* gave a nominally significant evidence of GxG interaction with this one SNP (Table 5). When all 38 SNPs in *FGF18* were examined with the 140 SNPs mapping to *FGF9*, several additional pairs of SNPs in these two genes showed further evidence of possible GxG interaction (see Figure 3). The most significant pairs involved SNPs in the intergenic region 3' of the gene, some are as far as 500kb away.

## DISCUSSION

In our analysis of 111 markers in 10 *FGF/FGFR* genes using 297 case–parent trios collected from an international study, SNPs in seven of these genes gave some evidence of linkage and association with unobserved causal variants for iCL±P. Genes in the *FGF/FGFR* pathway are considered good candidates for iCL±P because they play important roles in craniofacial development (Kurose et al., 2004; Rice et al., 2004; Jugessur et al., 2009) and several of them (*FGFR1*, *FGFR2*, and *FGF10*) control Mendelian malformation syndromes which can include oral clefts as a hallmark feature (Slaney et al., 1996; Dodéet al., 2003; Entesarian et al., 2005). Genes can contribute to the etiology of non–syndromic forms of oral clefts as well as Mendelian malformation syndromes, e.g. interferon regulatory factor 6 (Kondo et al., 2002; Zuccherio et al., 2004).

Fine mapping linkage scans in the 8p11–23 chromosomal region (Riley et al., 2007c), association and sequencing studies (Riley et al., 2007a; 2007b) offered further support for *FGFR1* as a good candidate for iCL±P. Our analysis of markers in *FGFR1* gene confirmed these previous reports. However, neither results from our or Riley's studies would retain statistical significance if strict Bonferroni correction for multiple testing were used. Although there is no previous evidence that *FGF19* influences risk to iCL±P, our results combined with evidence from animal models (Kurose et al., 2004) suggest further investigation of this gene may be warranted.

Mutations in non–coding regions of *FGF2* and *FGF10* can result in impaired transcription (Riley et al., 2007b). Our analysis showed intriguing evidence for maternal genotypic effects controlling the offspring's risk of iCL±P for markers in these two genes among Asians, though fetal effects identified in two previous studies for SNPs in *FGF10* (Riley et al., 2007b; Menezes et al., 2008) were not confirmed here. Maternal genes control the *in utero* environment, so potential maternal genotype effects of markers in *FGF2* and *FGF10* genes seen among our Asian trios may be important (Boyles et al., 2009).

Sequence analysis identified several rare mutations in coding regions of *FGFR2*, which may be causal (Riley et al., 2007a; 2007b). In our study, SNPs in *FGFR2* showed suggestive evidence of GxE interaction with maternal smoking and significant evidence of interaction with vitamin supplementation (even after Bonferroni correction). Evidence from association studies with markers in *FGFR2* across studies has been inconsistent (Riley et al., 2007a; Menezes et al., 2008), but our suggestion of GxE interaction deserves further investigation given the potential for public health intervention with modifiable environmental risk factors.

Potentially important mutations in non-coding regions of *FGF9* were identified in a separate sequencing study (Riley et al., 2007a; 2007b). Our analysis of 297 trios showed intriguing evidence for possible GxG interaction between *FGF18* and *FGF9* that may be important for iCL±P. Using independent trios from the International Cleft Consortium described by Beaty et al. (2010), we confirmed the significance of GxG interaction between markers in *FGF9* and *FGF18* identified in these 297 trios, although the strongest evidence was seen for markers distal to the 3' end of *FGF9* (well away from coding regions). The combination of statistical evidence from these 297 trios and from the 1434 independent trios from the GWAS makes it more likely these findings are biologically meaningful. Very few GWAS signals are actually found in coding sequences (Hindorf et al., 2009) and the strongest association signal for iCL±P in Europeans lies in an apparent “gene desert” on chromosome 8q24 (Birnbau et al., 2009; Grant et al., 2009; Beaty et al., 2010). Similar regulators may underlie these associations, and one can imagine a shared enhancer sequence could explain the suggested interaction between these two *FGF* genes.

Our association results confirmed some previous findings from published linkage, association and sequencing analysis for various *FGF/FGFR* genes, and provided new clues about how these different genes may act through potential maternal genotypic effects, GxE and GxG interactions to control risk of iCL±P. Although some of the statistical evidence presented here did not retain significance after strict Bonferroni correction, mechanisms of GxG interaction in particular require further investigation.

## Acknowledgments

We thank all participants who donated samples for this multi-center study of oral clefts, as well as the staff at each participating site and institution.

This research was supported by R21-DE-013707 and R01-DE-014581 from the National Institute of Dental & Craniofacial Research, and D43-TW006176 from Fogarty Institution.

## REFERENCES

- Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics*. 2005; 21:263–265. [PubMed: 15297300]
- Beatty TH, Murray JC, Marazita ML, Munger RG, Ruczinski I, Hetmanski JB, Liang KY, Wu T, Murray T, Fallin MD, et al. A genome-wide association study of cleft lip with and without cleft palate identifies risk variants near MAFB and ABCA4. *Nat Genet*. 2010; 42:525–529. [PubMed: 20436469]
- Birnbaum S, Ludwig KU, Reutter H, Herms S, Steffens M, Rubini M, Baluardo C, Ferrian M, Almeida de Assis N, Alblas MA, et al. Key susceptibility locus for nonsyndromic cleft lip with or without cleft palate on chromosome 8q24. *Nat Genet*. 2009; 41:473–477. [PubMed: 19270707]
- Boyles AL, Wilcox AJ, Taylor JA, Shi M, Weinberg CR, Meyer K, Fredriksen A, Ueland PM, Johansen AM, Drevon CA, et al. Oral facial clefts and gene polymorphisms in metabolism of folate/one-carbon and vitamin A: a pathway-wide association study. *Genet Epidemiol*. 2009; 33(3):247–255. [PubMed: 19048631]
- Cordell HJ. Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. *Hum Mol Genet*. 2002; 11:2463–2468. [PubMed: 12351582]
- Dodé C, Levilliers J, Dupont JM, De Paepe A, Le Dû N, Soussi-Yanicostas N, Coimbra RS, Delmaghani S, Compain-Nouaille S, Baverel F, et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. *Nat Genet*. 2003; 33:463–465. [PubMed: 12627230]
- Entesarian M, Matsson H, Klar J, Bergendal B, Olson L, Arakaki R, Hayashi Y, Ohuchi H, Falahat B, Bolstad AI, et al. Mutations in the gene encoding fibroblast growth factor 10 are associated with aplasia of lacrimal and salivary glands. *Nat Genet*. 2005; 37:125–127. [PubMed: 15654336]
- Grant SF, Wang K, Zhang H, Glaberson W, Annaiah K, Kim CE, Bradfield JP, Glessner JT, Thomas KA, Garris M, et al. A genome-wide association study identifies a locus for nonsyndromic cleft lip with or without cleft palate on 8q24. *J. Pediatr*. 2009; 155(6):909–913. [PubMed: 19656524]
- Grosen D, Chevrier C, Skytthe A, Bille C, Mølsted K, Sivertsen A, Murray JC, Christensen K. A cohort study of recurrence patterns among more than 54,000 relatives of oral cleft cases in Denmark: support for the multifactorial threshold model of inheritance. *J. Med Genet*. 2010; 47:162–168. [PubMed: 19752161]
- Hindorff LA, Sethupathy P, Junkins HA, Ramos EA, Mehta JP, Collins FS, Manolio TA. Potential etiologic and functional implications of genome wide association loci for human diseases and traits. *Proc Natl Acad Sci USA*. 2009; 106:9362–9367. [PubMed: 19474294]
- Jugessur A, Murray JC. Orofacial clefting: recent insights into a complex trait. *Curr Opin Genet Dev*. 2005; 15:270–278.
- Jugessur A, Farlie PG, Kilpatrick N. The genetics of isolated orofacial clefts: from genotypes to subphenotypes. *Oral Dis*. 2009; 15(7):437–453. [PubMed: 19583827]
- Kondo S, Schutte BC, Richardson RJ, Bjork BC, Knight AS, Watanabe Y, Howard E, de Lima RL, Daack-Hirsch S, Sander A, et al. Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes. *Nat Genet*. 2002; 32:285–289. [PubMed: 12219090]

- Kurose H, Bito T, Adachi T, Shimizu M, Noji S, Ohuchi H. Expression of Fibroblast growth factor 19 (Fgf19) during chicken embryogenesis and eye development, compared with Fgf15 expression in the mouse. *Gene Expression Patterns*. 2004; 4:687–693. [PubMed: 15465490]
- Laird NM, Lange C. Family-based designs in the age of large-scale gene-association studies. *Nat Rev Genet*. 2006; 7:385–394. [PubMed: 16619052]
- Marazita ML, Murray JC, Lidral AC, Arcos-Burgos M, Cooper ME, Goldstein T, Maher BS, Daack-Hirsch S, Schultz R, Mansilla MA, et al. Meta-analysis of 13 genome scans reveals multiple cleft lip/palate genes with novel loci on 9q21 and 2q32-35. *Am J Hum Genet*. 2004; 75:161–173. [PubMed: 15185170]
- Marazita ML, Lidral AC, Murray JC, Field LL, Maher BS, Goldstein McHenry T, Cooper ME, Govil M, Daack-Hirsch S, Riley B, et al. Genome scan, fine-mapping, and candidate gene analysis of non-syndromic cleft lip with or without cleft palate reveals phenotype-specific differences in linkage and association results. *Hum Hered*. 2009; 68(3):151–170. [PubMed: 19521098]
- Menezes R, Letra A, Ruff J, Granjeiro JM, Vieira AR. Studies of genes in the FGF signaling pathway and oral clefts with or without dental anomalies. *Am J Med Genet A*. 2008; 146A:1614–1617. [PubMed: 18478591]
- Mossey, PA.; Little, J. Epidemiology of oral clefts: an international perspective.. In: Wyszynski, DF., editor. *Cleft Lip and Palate*. Oxford University Press; New York: 2002. p. 127-158.
- Nie X, Luukko K, Kettunen P. FGF signalling in craniofacial development and developmental disorders. *Oral Dis*. 2006; 12:102–111. [PubMed: 16476029]
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. *Am J Hum Genet*. 2007; 81(3):559–575. [PubMed: 17701901]
- Rice R, Spencer-Dene B, Connor EC, Gritli-Linde A, McMahon AP, Dickson C, Thesleff I, Rice DP. Disruption of Fgf10/Fgfr2b-coordinated epithelial-mesenchymal interactions causes cleft palate. *J Clin Invest*. 2004; 113:1692–1700. [PubMed: 15199404]
- Riley BM, Mansilla MA, Ma J, Daack-Hirsch S, Maher BS, Raffensperger LM, Russo ET, Vieira AR, Dodé C, Mohammadi M, et al. Impaired FGF signaling contributes to cleft lip and palate. *Proc Natl Acad Sci*. 2007a; 104:4512–4517. [PubMed: 17360555]
- Riley BM, Murray JC. Sequence Evaluation of FGF and FGFR Gene Conserved Non-Coding Elements in Non-Syndromic Cleft Lip and Palate Cases. *Am J Med Genet A*. 2007b; 143A:3228–3234. [PubMed: 17963255]
- Riley BM, Schultz RE, Cooper ME, Goldstein-McHenry T, Daack-Hirsch S, Lee KT, Dragan E, Vieira AR, Lidral AC, Marazita ML, et al. A genome-wide linkage scan for cleft lip and cleft palate identifies a novel locus on 8p11-23. *Am J Med Genet A*. 2007c; 143A:846–852. [PubMed: 17366557]
- Shaw GM, Wasserman CR, Murray JC, Lammer EJ. Infant TGF-alpha genotype, orofacial clefts, and maternal periconceptional multivitamin use. *Cleft Palate Craniofac J*. 1998; 35:366–370. [PubMed: 9684776]
- Shi M, Christensen K, Weinberg CR, Romitti P, Bathum L, Lozada A, Morris RW, Lovett M, Murray JC. Orofacial cleft risk is increased with maternal smoking and specific detoxification gene variants. *Am J Hum Genet*. 2007a; 80:76–90. [PubMed: 17160896]
- Shi M, Umbach DM, Weinberg CR. Identification of risk-related haplotypes with the use of multiple SNPs from nuclear families. *Am J Hum Genet*. 2007b; 81:53–66. [PubMed: 17564963]
- Shi M, Umbach DM, Weinberg CR. Using case-parent triads to estimate relative risks associated with a candidate haplotype. *Ann Hum Genet*. 2009; 73(3):346–359. [PubMed: 19344450]
- Slaney SF, Oldridge M, Hurst JA, Moriss-Kay GM, Hall CM, Poole MD, Wilkie AO. Differential effects of FGFR2 mutations on syndactyly and cleft palate in Apert syndrome. *Am J Hum Genet*. 1996; 58:923–932. [PubMed: 8651276]
- Sull JW, Liang KY, Hetmanski JB, Wu T, Fallin MD, Ingersoll RG, Park JW, Wu-Chou YH, Chen PK, Chong SS, et al. Evidence that TGFA influences risk to cleft lip with/without cleft palate through unconventional genetic mechanisms. *Hum Genet*. 2009; 126:385–394. [PubMed: 19444471]




- Weinberg CR, Wilcox AJ, Lie RT. A log-linear approach to case-parent-triad data: assessing effects of disease genes that act either directly or through maternal effects and that may be subject to parental imprinting. *Am J Hum Genet.* 1998; 62:969–978. [PubMed: 9529360]
- Zeiger JS, Beaty TH, Liang KY. Oral clefts, maternal smoking, and TGFA: a meta-analysis of gene-environment interaction. *Cleft Palate Craniofac J.* 2005; 42(1):58–63. [PubMed: 15643916]
- Zuccherro TM, Cooper ME, Maher BS, Daack-Hirsch S, Nepomuceno B, Ribeiro L, Caprau D, Christensen K, Suzuki Y, Machida J, et al. Interferon regulatory factor 6 (IRF6) gene variants and the risk of isolated cleft lip or palate. *N Engl J Med.* 2004; 351:769–780. [PubMed: 15317890]


\$watermark-text

\$watermark-text


\$watermark-text



**Figure 1.** Testing for main effects (G) of individual SNPs (haplotypes) of *FGFR2* and gene–environment interaction (GxE) for two common maternal exposures in 221CL/P case–parent trios from Asian populations. *Triangles* represent the 2 df test of G and GxE interaction, *squares* represent the 1 df test of G x E only. Haplotypes of 2- and 3-SNPs are connected by *solid lines* for 2df test and *dotted lines* for 1 df test (only nominally significant haplotypes are shown here). *rs2912762\**: The distance between *rs3135761* and *rs2912762* were drawn for clarity (true distance between these two SNPs is 199 base pairs).



**Figure 2.** Distribution of maximum LRT values over 1000 replicates. Histograms represent the frequency of maximum test statistics generated under the null hypothesis of no GxG interaction. The vertical line shows the position of observed test statistic of GxG interaction between *rs12870202* and *rs2043278*. About 1.9% of permuted test statistics exceeded this observed value, giving an empiric p-value corrected for multiple testing ( $p=0.019$ ).



**Figure 3.**

Significance [as  $-\log_{10}(p)$ ] from 4df LRT for Cordell's test of GxG interaction between markers in *FGF18* and *FGF9* plotted against the physical position in *FGF9*. SNP (*rs2043278*) in *FGF18* is an intronic marker located at 170,815,212 (Build 36) and showed moderately significant p-values for 11 different SNPs in *FGF9* (solid circles), most of which were located in the 3'UTR (some as far as 500 Kb away from the coding region of *FGF9*). Five additional SNPs in *FGF18* also yielded strong evidence of GxG interaction with SNPs in the intergenic region 3' of the *FGF9* coding region (open symbols).

\$watermark-text

\$watermark-text

\$watermark-text

**TABLE 1**

Gender and racial origin of 297 CL/P probands from 4 populations

Racial Origin	Maryland		Taiwan		Singapore		Korean		Total	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
European	41	29	0	0	1	1	0	0	42	30
African	3	3	0	0	0	0	0	0	3	3
Asian	0	0	95	51	23	10	22	18	140	79
Total	44	32	95	51	24	11	22	18	185	112

\$watermark-text

\$watermark-text

\$watermark-text

**TABLE 2**

SNPs yielding significant or marginally significant associations from analysis of 111 markers in 10 *FGF/FGFR* genes from family based association tests for single SNPs and 2-5 SNP haplotypes in analysis of 76 MD trios and 221 Asian trios separately

Site	Gene	SNP name	Risk allele/haplotype	%	# informative Families	T	NT	OR (95%CI)	P Value
Single SNP Analysis									
Asian	<i>FGF19</i>	RS3737463	1	66.6	148	112	78	1.44(1.07-1.94)	0.0136
Asian	<i>FGF19</i>	RS948992	2	55.4	148	114	83	1.37(1.03-1.85)	0.0272
MD	<i>FGF19</i>	RS1789364	2	38.9	33	28	15	1.87(0.96-3.76)	0.0474
MD	<i>FGF2</i>	RS308395	1	18.8	18	14	5	2.80(0.95-9.93)	0.0640
Haplotype Analysis									
Asian	<i>FGFR1</i>	RS6987534 RS6474354 RS10958700	2,2,1	12.4	79	28	55	0.51(0.31-0.82)	0.0411
Asian	<i>FGF19</i>	RS3737463 RS948992	1,2	45.1	145	117	82	1.43(1.07-1.92)	0.0271
Asian	<i>FGF19</i>	RS3737463 RS948992 RS1307968	1,2,1	45.1	142	119	82	1.45(1.09-1.95)	0.0161
Asian	<i>FGF19</i>	RS3737463 RS948992 RS1307968 RS1320706	1,2,1,1	45.3	142	116	80	1.45(1.08-1.95)	0.0272
Asian	<i>FGF19</i>	RS3737463 RS948992 RS1307968 RS1320706	1,2,1,1,1	36.2	126	101	77	1.31(0.97-1.79)	0.0498

\$watermark-text

\$watermark-text

\$watermark-text

**TABLE 3**

Maternal risk haplotypes identified by TRIMM from analysis of 28 markers in the *FGF2* and *FGF10* genes under an additive model where maternal genotype alone ( $S_1$ ) controls risk to CL/P in offspring from TRIMMEST analysis in 221 Asian trios.

Gene (#Chr)	#SNPs	Sum_logP	SNPs	Risk Allele	Estimated risk for Mat. Hap. $S_1$	Risk Hap Freq			$\chi^2$	P
						0	1	2		
<i>FGF2</i> (4)	12	0.024	<i>RS5789138</i>	1	1.72	0.22	0.52	0.26	11.47	0.0007
			<i>RS308388</i>	1						
			<i>RS1476214</i>	1						
			<i>RS1476217</i>	2						
<i>FGF10</i> (5)	16	0.027	<i>RS10057630</i>	1	1.61		0.25		7.29	0.0069
			<i>RS1448037</i>	1						
			<i>RS593307</i>	1						
			<i>RS339502</i>	2						
			<i>RS1384449</i>	2						
			<i>RS2973647</i>	1						

TABLE 4

Significant tests for G×G interaction among 111 markers in 10 different *FGF/FGFR* genes in 297 CL/P case-parent trios from 4 populations based on 4df LRT testing for 2-way interaction

First gene		Second gene		Marker 1	Marker 2	Test statistic	P-value
Gene snp1	Chr snp1	Gene snp2	Chr snp2	SNP1	SNP2		
<i>FGF18</i>	5	<i>FGF10</i>	5	RS4559013	RS11750845	14.255	0.0065
<i>FGF18</i>	5	<i>FGF10</i>	5	RS4076077	RS11750845	14.300	0.0064
<i>FGF18</i>	5	<i>FGF10</i>	5	RS4076077	RS1482679	14.156	0.0068
<i>FGF18</i>	5	<i>FGF10</i>	5	RS3934591	RS1482679	17.743	0.0014
<i>FGF18</i>	5	<i>FGFR1</i>	8	RS6887323	RS2978073	13.604	0.0087
<i>FGF18</i>	5	<i>FGF3</i>	11	RS6887323	RS1893047	15.135	0.0044
<i>FGF18</i>	5	<i>FGF3</i>	11	RS2043278	RS11263592	14.199	0.0067
<i>FGF18</i>	5	<i>FGF3</i>	11	RS2043278	RS1893047	13.958	0.0074
<b><i>FGF18</i></b>	<b>5</b>	<b><i>FGF9</i></b>	<b>13</b>	<b>RS2043278</b>	<b>RS12870202</b>	<b>23.854</b>	<b>0.0001*</b>
<i>FGFR2</i>	10	<i>FGF10</i>	5	RS2981430	RS593307	13.556	0.0089
<i>FGFR2</i>	10	<i>FGF10</i>	5	RS2981430	RS339502	13.815	0.0079
<i>FGFR2</i>	10	<i>FGF10</i>	5	RS2981430	RS1384449	14.338	0.0063
<i>FGFR2</i>	10	<i>FGFR1</i>	8	RS2981427	RS4733930	15.973	0.0031
<i>FGF3</i>	11	<i>FGFBP1</i>	4	RS11263592	RS732245	13.590	0.0087
<i>FGF3</i>	11	<i>FGFBP1</i>	4	RS11263587	RS732245	13.563	0.0088
<i>FGF9</i>	13	<i>FGFR1</i>	8	RS6490667	RS4733930	14.010	0.0073

\* Only this 2-SNP interaction remained significant after 1,000 permutations with P-value of 0.019.



**TABLE 5**

Tests for G×G interaction between *RS2043278* in *FGF18* and 11 SNPs in *FGF9* that achieved nominal significance in 1434 case-parent trios from the International Cleft Consortium

SNP_pair	Position in <i>FGF9</i>	Statistic	Nominal P
<i>RS2043278: RS829209</i>	21133584	10.05	0.0396
<i>RS2043278: RS9634328</i>	21136546	10.71	0.0300
<i>RS2043278: RS672905</i>	21281253	9.42	0.0514
<i>RS2043278: RS7999069</i>	21284490	12.27	0.0154
<i>RS2043278: RS17073403</i>	21383899	9.61	0.0475
<i>RS2043278: RS7338014</i>	21384015	10.77	0.0293
<i>RS2043278: RS9580272</i>	21474452	13.59	0.0087
<i>RS2043278: RS12853883</i>	21529175	10.16	0.0378
<i>RS2043278: RS725600</i>	21643202	10.70	0.0301
<i>RS2043278: RS9552612</i>	21652578	11.60	0.0205
<i>RS2043278: RS17326684</i>	21667539	10.52	0.0325